Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fulcrum Therapeutics (FULC) Amortizatization of Intangibles (2020 - 2025)

Fulcrum Therapeutics (FULC) has disclosed Amortizatization of Intangibles for 6 consecutive years, with $383000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Amortizatization of Intangibles fell 59.47% to $383000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $3.0 million, a 32.76% decrease, with the full-year FY2025 number at $3.0 million, down 32.76% from a year prior.
  • Amortizatization of Intangibles was $383000.0 for Q4 2025 at Fulcrum Therapeutics, down from $586000.0 in the prior quarter.
  • In the past five years, Amortizatization of Intangibles ranged from a high of $1.7 million in Q2 2023 to a low of -$386000.0 in Q4 2021.
  • A 5-year average of $625550.0 and a median of $750000.0 in 2022 define the central range for Amortizatization of Intangibles.
  • Peak YoY movement for Amortizatization of Intangibles: plummeted 1002.86% in 2021, then skyrocketed 1515.18% in 2023.
  • Fulcrum Therapeutics' Amortizatization of Intangibles stood at -$386000.0 in 2021, then soared by 255.7% to $601000.0 in 2022, then skyrocketed by 120.97% to $1.3 million in 2023, then fell by 28.84% to $945000.0 in 2024, then plummeted by 59.47% to $383000.0 in 2025.
  • Per Business Quant, the three most recent readings for FULC's Amortizatization of Intangibles are $383000.0 (Q4 2025), $586000.0 (Q3 2025), and $1.1 million (Q2 2025).